Black checkmark with a sparkle and a curved line underneath on a white background.
Company

MetaVia Inc.

Ticker
MTVA
Sector
Industry
Report date
November 13, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments for MetaVia include positive interim and statistically significant clinical trial data for DA-1726, patent portfolio expansions, management appointments, and capital raising activities.

Recent developments:
  • MetaVia announced statistically significant reduction in uric acid levels with DA-1726 in Phase 1 Part 3B clinical trial, supporting its liver-focused cardiometabolic profile [N1].
  • Positive interim data from Part 3B of Phase 1 clinical trial of DA-1726 showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at Day 109 [N2].
  • MetaVia presented Phase 1 clinical trial data for DA-1726 at the Precision Liver Symposium 2026 [N3].
  • Sarah Browne was appointed as Chief Medical Officer in October 2026 [N4].
  • The company completed dose titration in the 16-week Phase 1 Part 3 study of DA-1726, with patients reaching highest planned dose levels [S2].
  • MetaVia secured global patent protection for DA-1726 through 2041 and for vanoglipel through 2035, providing broad intellectual property coverage [S1].
  • MetaVia closed an underwritten public offering in January 2026, raising approximately $9.3 million gross proceeds [S1].
  • The company reported increased R&D expenses related to DA-1726 clinical trial activities and increased G&A expenses due to legal, consulting, and employee costs [S2].
  • MetaVia faces substantial doubt about its ability to continue as a going concern within one year due to ongoing net losses and cash burn [S2].
Overview

MetaVia Inc. operates as a clinical-stage biotechnology company specializing in the development of novel pharmaceuticals aimed at treating liver-focused cardiometabolic diseases such as MASLD, MASH, MetALD, and ALD. The company’s pipeline centers on two main drug candidates: vanoglipel (DA-1241), a GPR119 agonist with potential as a standalone or combination therapy for MASLD and MASH, and DA-1726, a dual agonist of GLP-1 and glucagon receptors designed for obesity and related metabolic conditions. MetaVia’s operations primarily involve research and development activities, including preclinical studies and clinical trials, with no current product revenue. The company has secured extensive patent protections for its drug candidates and has conducted multiple clinical trials, reporting positive interim and top-line data. Financially, MetaVia has experienced significant operating losses and negative cash flows since inception, with liquidity sufficient to fund operations into late 2026. The company completed a reverse stock split in late 2025 and raised capital through a public offering in early 2026. Management changes and ongoing clinical trial progress are notable recent developments.

Executive summary

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for liver-focused cardiometabolic diseases. Its primary clinical programs are vanoglipel (DA-1241), a GPR119 agonist targeting MASLD and MASH, and DA-1726, a GLP-1 and glucagon receptor dual agonist for obesity and related conditions. The company has reported positive clinical trial data for both programs, including statistically significant reductions in liver fat, weight loss, and uric acid levels with DA-1726. MetaVia holds global patent protections for its key drug candidates extending through 2035 and 2041. Financially, the company has incurred significant operating losses and negative cash flows, with $8.8 million in cash as of September 30, 2026, and liquidity ratios indicating funding into late 2026. MetaVia completed a reverse stock split in December 2025 and raised approximately $9.3 million in a January 2026 public offering. The company faces substantial doubt about its ability to continue as a going concern within one year due to ongoing losses and cash burn. Recent developments include management appointments, clinical data presentations, and ongoing clinical trial progress. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for MTVA

Bull case model:

MetaVia’s positive clinical trial data for DA-1726, including statistically significant reductions in liver fat, weight loss, and uric acid levels, demonstrate potential therapeutic benefits in liver-focused cardiometabolic diseases. The company’s robust patent portfolio and exclusive licensing agreements provide intellectual property protection. Ongoing clinical development of vanoglipel and DA-1726, combined with strategic collaborations and recent capital raises, support continued advancement of its pipeline. Management appointments and presentations at scientific conferences indicate organizational strengthening and engagement with the medical community.

Bear case model:

MetaVia faces substantial risks inherent to clinical-stage biotechnology companies, including the uncertainty of clinical trial outcomes, regulatory approvals, and the ability to secure sufficient funding. The company has incurred significant operating losses and negative cash flows, with liquidity raising doubt about its ability to continue as a going concern beyond late 2026. Delays or failures in clinical development, inability to protect intellectual property, competitive pressures, and challenges in commercialization could materially impact the company’s prospects. Additionally, reliance on equity financing may result in dilution for existing shareholders.

Moat:

MetaVia’s moat is primarily based on its proprietary drug candidates with novel mechanisms targeting liver-focused cardiometabolic diseases, supported by extensive global patent protection extending through 2035 and 2041. The company’s exclusive licensing agreements and intellectual property portfolio provide barriers to entry for competitors. Additionally, MetaVia’s clinical-stage pipeline with positive early clinical data and its collaborations leveraging AI-driven drug discovery platforms contribute to its competitive positioning. However, as a clinical-stage biotech company without commercial products, its moat is contingent on successful clinical development, regulatory approvals, and eventual commercialization.

Risks overview
Risks summary
The most significant risk for MetaVia is its financial position, with ongoing net losses and limited liquidity raising substantial doubt about its ability to continue as a going concern without securing additional funding.
Risks details:

• Clinical Development Risk: MetaVia’s drug candidates are in early clinical stages with inherent uncertainties regarding safety, efficacy, and regulatory approval outcomes.
• Financial Risk: The company has experienced significant losses and negative cash flows, with liquidity sufficient only into late 2026, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Regulatory Risk: Obtaining regulatory approvals involves complex processes with no assurance of success, which could delay or prevent commercialization.
• Intellectual Property Risk: While MetaVia holds extensive patents, challenges in maintaining, defending, or enforcing these rights could affect competitive positioning.
• Market and Competitive Risk: Competition from other companies developing treatments for liver and metabolic diseases may impact MetaVia’s market opportunities.

FINAL FORECAST FOR MTVA

Final take one line
MetaVia Inc. is a clinical-stage biotech with detailed disclosures on its liver-focused cardiometabolic drug pipeline, positive clinical data, patent protections, and financial challenges including liquidity concerns.
Final take 12 to 24 month view

Business trends: Continued clinical development of DA-1726 and vanoglipel with emerging positive clinical data and expanding intellectual property portfolio.
Execution milestones: Completion and reporting of Phase 1 and Phase 2 clinical trial data, regulatory interactions, and capital raising activities.
Key risks: Clinical trial uncertainties, regulatory approval challenges, financial sustainability concerns, and competitive market pressures.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat liver-focused cardiometabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-related liver disease (ALD).
  • The company has two main clinical programs: vanoglipel (DA-1241), a GPR119 agonist targeting MASLD and MASH, and DA-1726, a novel oxyntomodulin analog acting as a GLP-1 receptor and glucagon receptor dual agonist for obesity and cardiometabolic conditions.
  • Vanoglipel has completed a Phase 2a clinical trial with data showing clinically meaningful improvements in glucose control, liver health, and plasma lipidomic profiles after 16 weeks of treatment.
  • DA-1726 is in Phase 1 clinical trials with multiple parts (3a and 3b) involving dose titration studies to evaluate safety, tolerability, and efficacy signals such as weight loss and liver fat reduction.
  • Recent Phase 1 Part 3B interim data for DA-1726 showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at Day 109, with all participants with baseline steatosis achieving MRI-PDFF below 5%.
  • Additional Phase 1 Part 3B data demonstrated a statistically significant reduction in uric acid levels after 16 weeks of DA-1726 treatment, supporting its liver-focused cardiometabolic profile.
  • MetaVia has secured global patent protection for DA-1726 through at least 2041 and for vanoglipel through at least 2035, with patents covering novel peptide structures, dual-incretin design, manufacturing, and therapeutic uses.
  • The company completed a one-for-eleven reverse stock split in December 2025, adjusting share counts and exercise prices accordingly.
  • MetaVia's operations primarily consist of research and development activities, including preclinical studies and clinical trials, with no current product revenue.
  • The company has incurred significant operating losses and negative cash flows since inception, with a net loss of $13.8 million for the nine months ended September 30, 2026, and an accumulated deficit of $162.6 million as of that date.
  • As of September 30, 2026, MetaVia had $8.8 million in cash and cash equivalents, a current ratio of 1.32, and a cash ratio of 1.24, indicating liquidity to fund operations into late 2026.
  • MetaVia raised approximately $9.3 million gross proceeds in an underwritten public offering in January 2026.
  • Research and development expenses increased in 2026 compared to 2025, primarily due to increased activities related to the DA-1726 Phase 1 clinical trial.
  • General and administrative expenses increased modestly in 2026 compared to 2025, driven by higher legal, consulting, and employee compensation costs.
  • The company appointed Sarah Kaplan Browne, M.D., as Chief Medical Officer in October 2026.
  • MetaVia plans to continue funding operations through equity offerings, debt financing, warrant exercises, collaborations, or out-licensing arrangements.
  • The company faces substantial doubt about its ability to continue as a going concern within one year from the issuance of its financial statements due to ongoing net losses and cash burn.
  • MetaVia has four legacy therapeutic programs that are not currently being advanced and may be considered for out-licensing or divestiture.
  • Clinical development activities are central to MetaVia's business model, with significant costs and uncertainties associated with clinical trials, regulatory approvals, manufacturing, and commercialization.
  • The company has disclosed detailed risk factors related to clinical development, regulatory approval, intellectual property, financing, and market competition.
  • MetaVia's recent news includes multiple announcements of positive clinical trial data for DA-1726, patent protections, management appointments, and capital raises.
  • The company presented data at scientific conferences such as ObesityWeek 2025 and the Precision Liver Symposium 2026.
  • MetaVia's Phase 1 clinical trial for DA-1726 includes dose titration studies to evaluate safety and efficacy signals, with data releases planned for early 2027.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | MetaVia Inc. Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial | https://www.nasdaq.com/articles/metavia-inc-announces-statistically-significant-reduction-uric-acid-levels-da-1726-phase-1
  • N2 | 2026-11-06 | www.nasdaq.com | MetaVia Inc. Announces Positive Interim Data from Part 3B of Phase 1 Clinical Trial of DA-1726 | https://www.nasdaq.com/articles/metavia-inc-announces-positive-interim-data-part-3b-phase-1-clinical-trial-da-1726
  • N3 | 2026-10-28 | www.nasdaq.com | MetaVia Inc. to Present Phase 1 Clinical Trial Data for DA-1726 at Precision Liver Symposium 2026 | https://www.nasdaq.com/articles/metavia-inc-present-phase-1-clinical-trial-data-da-1726-precision-liver-symposium-2026
  • N4 | 2026-10-13 | www.nasdaq.com | MetaVia Appoints Sarah Browne As CMO | https://www.nasdaq.com/articles/metavia-appoints-sarah-browne-cmo
  • N5 | 2026-06-09 | www.nasdaq.com | Pre-Market Movers: RGNT, FEED, BYAH Swing Big | https://www.nasdaq.com/articles/pre-market-movers-rgnt-feed-byah-swing-big
  • N6 | 2026-05-26 | www.nasdaq.com | Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-aktx-rallies-govx-ebola-concerns-slgl-awaits-catalysts-cmmb-watch
  • N7 | 2026-05-20 | www.nasdaq.com | MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch | https://www.nasdaq.com/articles/mtva-gains-weight-codx-takes-shot-ebola-edsa-reveal-new-data-bdtx-watch
  • N8 | 2026-03-26 | www.nasdaq.com | NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes | https://www.nasdaq.com/articles/neurobo-pharmaceuticals-rebrands-amidst-strategic-changes
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine